Biomarkers in gastrointestinal cancers

Rami Badreddine, Kenneth Ke Ning Wang

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We have summarized the characteristics of the clinically useful or potentially useful biomarkers in a number of GI cancers. This field is growing, and the predictive and diagnostic value of the biomarkers as a measure of carcinogenesis is still in evolution. It is essential for the clinician to have an understanding of the basic molecular biology behind GI cancers because, in the future, many clinicians will be routinely ordering biomarker testing as part of patient screening. The biomarkers in GI cancers are useful not only for screening, diagnosis, and prognosis but also for prediction of the response to mechanism-based interventions, such as chemoprevention. Ongoing assessment of these diagnostic and predictive factors will probably lead to a change in the current staging of many GI cancers.

Original languageEnglish (US)
Pages (from-to)2106-2110
Number of pages5
JournalAmerican Journal of Gastroenterology
Volume103
Issue number8
DOIs
StatePublished - Aug 2008

Fingerprint

Gastrointestinal Neoplasms
Biomarkers
Neoplasms
Chemoprevention
Molecular Biology
Carcinogenesis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Biomarkers in gastrointestinal cancers. / Badreddine, Rami; Wang, Kenneth Ke Ning.

In: American Journal of Gastroenterology, Vol. 103, No. 8, 08.2008, p. 2106-2110.

Research output: Contribution to journalArticle

Badreddine, Rami ; Wang, Kenneth Ke Ning. / Biomarkers in gastrointestinal cancers. In: American Journal of Gastroenterology. 2008 ; Vol. 103, No. 8. pp. 2106-2110.
@article{0975005b69c145548e68798649df3397,
title = "Biomarkers in gastrointestinal cancers",
abstract = "We have summarized the characteristics of the clinically useful or potentially useful biomarkers in a number of GI cancers. This field is growing, and the predictive and diagnostic value of the biomarkers as a measure of carcinogenesis is still in evolution. It is essential for the clinician to have an understanding of the basic molecular biology behind GI cancers because, in the future, many clinicians will be routinely ordering biomarker testing as part of patient screening. The biomarkers in GI cancers are useful not only for screening, diagnosis, and prognosis but also for prediction of the response to mechanism-based interventions, such as chemoprevention. Ongoing assessment of these diagnostic and predictive factors will probably lead to a change in the current staging of many GI cancers.",
author = "Rami Badreddine and Wang, {Kenneth Ke Ning}",
year = "2008",
month = "8",
doi = "10.1111/j.1572-0241.2008.01994.x",
language = "English (US)",
volume = "103",
pages = "2106--2110",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Biomarkers in gastrointestinal cancers

AU - Badreddine, Rami

AU - Wang, Kenneth Ke Ning

PY - 2008/8

Y1 - 2008/8

N2 - We have summarized the characteristics of the clinically useful or potentially useful biomarkers in a number of GI cancers. This field is growing, and the predictive and diagnostic value of the biomarkers as a measure of carcinogenesis is still in evolution. It is essential for the clinician to have an understanding of the basic molecular biology behind GI cancers because, in the future, many clinicians will be routinely ordering biomarker testing as part of patient screening. The biomarkers in GI cancers are useful not only for screening, diagnosis, and prognosis but also for prediction of the response to mechanism-based interventions, such as chemoprevention. Ongoing assessment of these diagnostic and predictive factors will probably lead to a change in the current staging of many GI cancers.

AB - We have summarized the characteristics of the clinically useful or potentially useful biomarkers in a number of GI cancers. This field is growing, and the predictive and diagnostic value of the biomarkers as a measure of carcinogenesis is still in evolution. It is essential for the clinician to have an understanding of the basic molecular biology behind GI cancers because, in the future, many clinicians will be routinely ordering biomarker testing as part of patient screening. The biomarkers in GI cancers are useful not only for screening, diagnosis, and prognosis but also for prediction of the response to mechanism-based interventions, such as chemoprevention. Ongoing assessment of these diagnostic and predictive factors will probably lead to a change in the current staging of many GI cancers.

UR - http://www.scopus.com/inward/record.url?scp=49349099864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49349099864&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2008.01994.x

DO - 10.1111/j.1572-0241.2008.01994.x

M3 - Article

C2 - 18637088

AN - SCOPUS:49349099864

VL - 103

SP - 2106

EP - 2110

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -